Cargando…
Longitudinal SARS-CoV-2 humoral response in MS patients with and without SARS-CoV-2 infection prior to vaccination
INTRODUCTION: During the COVID-19 pandemic, certain disease modifying therapies (DMTs) used in multiple sclerosis (MS), such as anti-CD20 therapies, have been associated with decreased humoral responses after SARS-CoV-2 vaccination. Hybrid immunity, referring to immunity after both vaccination and S...
Autores principales: | van Dam, Koos P. J., Hogenboom, Laura, Stalman, Eileen W., Kummer, Laura Y. L., Steenhuis, Maurice, Keijser, Jim B. D., Brinke, Anja ten, van Ham, S. Marieke, Kuijpers, Taco W., Rispens, Theo, Wieske, Luuk, Eftimov, Filip, Strijbis, Eva M., Killestein, Joep, van Kempen, Zoé L. E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9686308/ https://www.ncbi.nlm.nih.gov/pubmed/36438945 http://dx.doi.org/10.3389/fneur.2022.1032830 |
Ejemplares similares
-
Ocrelizumab Concentration Is a Good Predictor of SARS‐CoV‐2 Vaccination Response in Patients with Multiple Sclerosis
por: van Kempen, Zoé L. E., et al.
Publicado: (2022) -
Severe breakthrough COVID-19 after SARS-CoV-2 booster vaccination in an MS patient on ocrelizumab
por: van Kempen, Zoé L.E., et al.
Publicado: (2022) -
Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod
por: Palomares Cabeza, Virginia, et al.
Publicado: (2022) -
Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: To wait and repopulate?
por: van Kempen, Z.L.E., et al.
Publicado: (2022) -
Immune dynamics in SARS-CoV-2 experienced immunosuppressed rheumatoid arthritis or multiple sclerosis patients vaccinated with mRNA-1273
por: Verstegen, Niels JM, et al.
Publicado: (2022)